| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 81 | 신경퇴행성 질환의 치료 | KR1020167018593 | 2014-12-12 | KR1020160089528A | 2016-07-27 | 퀸타나,프란시스코제이.; 마요,리오르; 웨이너,하워드; 할스,레자 |
| 대상체에서 MS, 예를들어 2차진행성다발성경화증(SPMS)을진단하거나이의발병위험을결정하는, 락토실세라미드(LacCer)의수준을검출하는것을기반으로하는, 방법이개시된다. 또한, 예를들어 LacCer 합성억제제의투여를포함하는, SPMS를치료하는방법이개시된다. | ||||||
| 82 | 고밀도 리포단백질3 중의 콜레스테롤의 정량 방법 및 정량 시약 | KR1020167001896 | 2014-07-24 | KR1020160030194A | 2016-03-16 | 사토노리유키; 이토야스키 |
| 번잡한조작을필요로하지않고, 피검시료중의 HDL 3을정량하는방법및 시약이개시되어있다. 고밀도리포단백질3 중의콜레스테롤의정량방법은피검시료에고밀도리포단백질3과특이적으로반응하는 1종또는 2종이상의계면활성제를반응시켜콜레스테롤을정량하는것을포함한다. 계면활성제가 1종인경우, 계면활성제는 HLB가 12.5~15인폴리옥시에틸렌다환페닐에테르로이루어지는군에서선택되는 1종이다. 계면활성제가 2종이상인경우, 계면활성제중 적어도 1종이폴리옥시에틸렌다환페닐에테르로이루어지는군에서선택되는적어도 1종이고, 또한 2종이상의계면활성제전체의 HLB가 12.5~15로되도록 2종이상의계면활성제를조합시킨다. | ||||||
| 83 | 미코플라스마·뉴모니애의 글리세로형 당지질 항원 | KR1020097000608 | 2007-06-13 | KR101488536B1 | 2015-02-10 | 마쯔다가즈히로; 신구유코 |
| 본 발명은, 미코플라스마·뉴모니애가 생산되는 신규 글리세로형 당지질을 제공하는 것을 과제로 한다. 또한, 본 발명의 글리세로형 당지질은 미코플라스마·뉴모니애를 병원(病原)으로 하는 질환의 진단용 마커로서 사용할 수 있다. | ||||||
| 84 | 자기공명분광법을 이용한 세포증식 및 분화 상태의 비침습적 측정방법, 이에 이용되는 자기공명분광용 세포 증식 및 분화마커 | KR1020120083135 | 2012-07-30 | KR101333665B1 | 2013-11-27 | 문치웅; 장무영; 천송이; 강복만; 곽소영 |
| The present invention relates to non-invasive measurement for a cell signal, and a method thereof and, more particularly, to a measuring method which checks the proliferation and differentiation states of a cell using magnetic resonance spectroscopy and objectively evaluates the state of the cell by enabling the reuse of the cell. The purpose of the present invention is to provide a bio marker capable of checking proliferation and differentiation information of each cell, is to provide a measuring method capable of reusing the cell by non-invasively measuring a cell signal using magnetic resonance spectroscopy (MRS) which is a non-invasive device, and to provide an effect of significantly shortening costs and time used for one experiment. [Reference numerals] (a,e) Cytology specimen;(b) Magnetic spectra signal data;(c) Data normalization;(d) Differentiation marker decision;(f) Metabolome magnetic spectra data;(g) Cell differentiation condition determination | ||||||
| 85 | 암 마커의 확인 방법 및 암 진단에서의 이의 용도 | KR1020037000848 | 2001-07-19 | KR1020030031126A | 2003-04-18 | 파리쉬,크리스토퍼,리차드; 카발다-크레인,비비안,메이 |
| 본 발명은 질량 분석법을 기초로 혈청에서 암 마커를 확인하는 방법 및 인간 및 인간이 아닌 대상체에서 암을 진단하는데 있어서의 상기 암 마커의 용도를 제공한다. 또한, 본 발명은 단리된 암 마커를 제공한다. | ||||||
| 86 | Peptide-lipid constructs and their use in diagnostic and therapeutic applications | US13765314 | 2013-02-12 | US10082515B2 | 2018-09-25 | Cristina-Simona Weinberg; Nicolai Bovin; Stephen Micheal Henry |
| Method of incorporating a water soluble construct of the structure L-S-F into the lipid bi-layer of cells by contacting a suspension of the cells with a solution of the construct at a concentration and for a time and temperature sufficient to allow the construct to insert into the lipid bi-layer. In the structure L-S-F, F is a peptide, S is a spacer containing an oligomer of ethylene glycol covalently linking F to L and the number of ethylene oxide repeats in the oligomer of ethylene glycol is 6 to 14, and L is a phosphatidylethanolamine. | ||||||
| 87 | Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps | US15458568 | 2017-03-14 | US10006925B2 | 2018-06-26 | Marko Bitenc; Kristi Kruusmaa; Paola Hurtado Castillo; Ana María Jiménez Girón; Rosa Argamasilla Martinez; Andreu Fabregat Rossell; Antonio Jesus Adsuar Gomez; Juan Martinez-Barea; Christian Hense; Patricia Rodríguez Gómez; Ángela Peralbo Molina; Jorge Casado Agrelo; Alejandro Sánchez Brotons; Cristina Pavón Solís; Rosa María Delgado Sánchez |
| Described herein are sets of metabolite and lipid (e.g., fatty acid) markers that can be used in the detection of early stage colorectal cancer and/or early development of adenomatous polyps. Presented herein are illustrative pathology-linked panels. In certain embodiments, the markers presented herein (or subsets thereof) are used as a panel for detecting either colorectal cancer or adenomatous polyps at the same time. The markers presented herein include metabolites and lipids (e.g., fatty acid) freely detectable and accurately quantifiable in human serum. In certain embodiments, the sample may be plasma, urine, saliva, whole blood, dried blood spot or dried serum spot. | ||||||
| 88 | Method of forming a lipid bilayer | US15526919 | 2015-11-19 | US09952195B2 | 2018-04-24 | Dac Nguyen; Basil Hanss |
| The present application is directed, at least in part, to a process for forming droplet interface blayers (DIBs). In one or more embodiments, a housing is produced wherein the housing includes at least one aperture that comprises a cis portion and a trans portion, at least one cis electrode receptacle and at least one trans electrode receptacle, wherein the cis electrode receptacle is operatively connected to the cis portion, and the trans electrode receptacle is operatively connected to the trans portion. In at least one embodiment, the number of cis and trans electrode receptacles equals the number of apertures. Electrodes are treated with a buffer and then inserted into each of the cis and trans electrode receptacles. | ||||||
| 89 | Treating neurodegenerative disease | US15103632 | 2014-12-12 | US09927437B2 | 2018-03-27 | Francisco J. Quintana; Lior Mayo; Howard Weiner; Reza Halse |
| As described herein, lactosylceramide (LacCer) levels are up-regulated in the CNS during chronic experimental autoimmune encephalomyelitis (EAE), an experimental model of multiple sclerosis (MS). LacCer acts in an autocrine manner to trigger transcriptional programs that promote the recruitment and activation of CNS infiltrating monocytes and microglia, and neurodegeneration. In addition, increased B4GALT6 expression and LacCer levels were detected in CNS MS lesions in human patients. Finally, the inhibition of LacCer synthesis suppressed local CNS innate immunity and neurodegeneration in EAE, and interfered with the activation of human astrocytes in vitro. Thus, B4GALT6 is a therapeutic target for MS and other neuroinflammatory disorders. | ||||||
| 90 | Cell Population Analysis | US15555694 | 2016-03-07 | US20180059126A1 | 2018-03-01 | Emrys JONES; Steven Derek PRINGLE; Keith RICHARDSON; James Ian LANGRIDGE; Zoltan TAKATS |
| A method of analysis using mass spectrometry and/or ion mobility spectrometry is disclosed comprising: (a) using a first device to generate smoke, aerosol or vapour from a target in vitro or ex vivo cell population; (b) mass analysing and/or ion mobility analysing said smoke, aerosol or vapour, or ions derived therefrom, in order to obtain spectrometric data; and (c) analysing said spectrometric data in order to identify and/or characterise said target cell population or one or more cells and/or compounds present in said target cell population. | ||||||
| 91 | Spectrometric Analysis of Microbes | US15556022 | 2016-03-07 | US20180057852A1 | 2018-03-01 | Zoltan TAKATS; Frances BOLT; Tamas KARANCSI; Emrys JONES; Keith RICHARDSON; Lajos GODORHAZY; Daniel SZALAY; Julia BALOG; Steven Derek PRINGLE; Daniel SIMON |
| A method of analysis using mass spectrometry and/or ion mobility spectrometry is disclosed. The method comprises: using a first device to generate smoke, aerosol or vapour from a target comprising or consisting of a microbial population; mass analysing and/or ion mobility analysing said smoke, aerosol or vapour, or ions derived therefrom, in order to obtain spectrometric data; and analysing said spectrometric data in order to analyse said microbial population. | ||||||
| 92 | Ambient Ionization Mass Spectrometry Imaging Platform for Direct Mapping from Bulk Tissue | US15555818 | 2016-03-07 | US20180047551A1 | 2018-02-15 | Emrys JONES; Steven Derek PRINGLE; Zoltan TAKATS |
| A method of ion imaging is disclosed that includes automatically sampling a plurality of different locations on a sample using a front device which is arranged and adapted to generate aerosol, smoke or vapour from the sample. Mass spectral data and/or ion mobility data corresponding to each location is obtained and the obtained mass spectral data and/or ion mobility data is used to construct, train or improved a sample classification model. | ||||||
| 93 | Chemically Guided Ambient Ionisation Mass Spectrometry | US15556064 | 2016-03-07 | US20180042583A1 | 2018-02-15 | Steven Derek PRINGLE; Emrys JONES; Michael Raymond MORRIS; Julia BALOG; James Ian LANGRIDGE; Keith RICHARDSON; Daniel SIMON; Lajos GODORHAZY; Daniel SZALAY; Zoltan TAKATS |
| A method is disclosed comprising obtaining or acquiring chemical or other non-mass spectrometric data from one or more regions of a target using a chemical sensor. The chemical or other non-mass spectrometric data may be used to determine one or more regions of interest of the target. An ambient ionisation ion source may then be used to generate aerosol, smoke or vapour from one or more regions of the target. | ||||||
| 94 | KIT AND METHOD | US15503627 | 2015-08-13 | US20170248595A1 | 2017-08-31 | Mark Stephen Baird; Christopher David Gwenin; Vanessa Valerie Gwenin; Joanne Louise Hacking; Mark Pitts |
| A method of determining the presence or absence in a sample of a biomarker, the method comprising the steps of (a) providing a porous substrate which carries an antigen; (b) contacting the substrate with the sample; (c) contacting the substrate with a composition comprising a secondary antibody; and (d) observing the substrate. The method may enable a very quick, simple test to be carried out to determine whether or not a particular sample contains a biomarker, for example an antibody indicative of infection with a mycobacterial disease. A kit and a device for determining the presence or absence in a sample of a biomarker are also described. | ||||||
| 95 | Cardiovascular disease risk assessment | US14943775 | 2015-11-17 | US09739790B2 | 2017-08-22 | Ernst J. Schaefer |
| The invention provides methods for analyzing cardiovascular disease risk. Methods of the invention provide a probability of an individual developing cardiovascular disease based on parameters including blood levels of sdLDL-C, ApoA-I in α-1 HDL, and Lp(a) along with information about the patient's age and history of blood pressure treatment, smoking, and diabetes. Methods of the invention do not rely on standard risk factor measurements, such as CRP, total cholesterol, body mass index, weight, triglycerides, and the like. | ||||||
| 96 | Non-invasive method for measuring proliferation and differentiation state of cells by using magnetic resonance spectroscopy, and cell proliferation and differentiation marker for magnetic spectroscopy used therefor | US14378092 | 2013-07-29 | US09714935B2 | 2017-07-25 | Chi Woong Mun; Moo Young Jang; Song I Chun; Bok Man Kang; So Young Kwak |
| Provided are a noninvasive measurement of cell signals and a method thereof, wherein the measurement method can ascertain cell proliferation and differentiation states using MRS and can enable cells to be reused so that cell states can be evaluated with improved reproducibility and reliability. And since the cell signals are noninvasively measured using the MRS, the corresponding cells can be reused so that the cost and time needed for one experiment can be remarkably reduced. | ||||||
| 97 | Method for treating metabolic syndrome | US14981130 | 2015-12-28 | US09713600B2 | 2017-07-25 | Stephanie Venn-Watson |
| Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight. | ||||||
| 98 | Method for detecting risk factor for metabolic syndrome or hyperferritinemia | US14980695 | 2015-12-28 | US09687461B2 | 2017-06-27 | Stephanie Venn-Watson |
| Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight. | ||||||
| 99 | Methods for Determining the Oncogenic Condition of Cell, Uses Thereof, and Methods for Treating Cancer | US15404473 | 2017-01-12 | US20170176446A1 | 2017-06-22 | Philippe De Medina; Michael Paillasse; Marc Poirot; Sandrine Silvente-Poirot |
| The invention relates to methods for detecting the oncogenic condition of cells, including step where the amount of the OCDO compound in said cells is measured, and to the uses thereof. The invention further relates to OCDO inhibitors for use in methods for treating cancer. | ||||||
| 100 | Compositions and methods for diagnosis and treatment of metabolic syndrome | US15030031 | 2015-12-21 | US09662306B2 | 2017-05-30 | Stephanie Venn-Watson |
| Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided. | ||||||
QQ群二维码
意见反馈
意见反馈